Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Deferred Revenue: 2019-2024

Historic Current Deferred Revenue for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $47.2 million.

  • C4 Therapeutics' Current Deferred Revenue fell 25.10% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 25.10%. This contributed to the annual value of $47.2 million for FY2024, which is 26.51% up from last year.
  • As of FY2024, C4 Therapeutics' Current Deferred Revenue stood at $47.2 million, which was up 26.51% from $37.3 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Current Deferred Revenue registered a high of $56.2 million during FY2021, and its lowest value of $27.6 million during FY2020.
  • Moreover, its 3-year median value for Current Deferred Revenue was $37.3 million (2023), whereas its average is $39.3 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 103.49% in 2021, then plummeted by 40.33% in 2022.
  • C4 Therapeutics' Current Deferred Revenue (Yearly) stood at $27.6 million in 2020, then skyrocketed by 103.49% to $56.2 million in 2021, then plummeted by 40.33% to $33.5 million in 2022, then rose by 11.26% to $37.3 million in 2023, then grew by 26.51% to $47.2 million in 2024.